Belite Bio, Inc.
(NASDAQ: BLTE)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $45.75 | Change: +0.25 | %Change: +0.55% | Volume: 24,454 |
Open: | $ 45.60 | Volume: | 24,454 | |
---|---|---|---|---|
High: | $ 46.24 | Yield(%) | 0.00 | |
Low: | $ 45.14 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 1.36B | |
EPS ($) | -1.18 | Shares Out: | 29.79M |
% Price Change (last 4 weeks): | -6.69 |
---|---|
% Price Change (last 13 weeks): | 19.23 |
% Price Change (last 26 weeks): | 6.41 |
% Price Change (last 52 weeks): | 218.18 |
% Price Change (year to date): | -0.55 |
Return on Equity (%): | -47.95 |
---|---|
Return on Assets (%): | -45.54 |
Return on Invested Capital (%): | -45.69 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $45.10 |
---|---|
200-day Moving Average: | $41.58 |
Avg. Daily Vol. (last 50 days): | 57,591 |
Avg. Daily Vol. (last 200 days): | 82,487 |
52-wk high: | $50.15 |
52-wk low: | $12.53 |
Bid: | $44.51 |
Ask: | $47.83 |
Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
|
Belite Bio, Inc.
12750 High Bluff Drive Suite 475 San Diego CA 92130 Phone: 1.858.246.6240 Fax: n/a http://www.belitebio.com |
Earnings (1year) ($): | -1.18 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 3.10 |
Cash Flow ($): | -1.07 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 14.75 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 24.76 |
---|---|
Current Ratio (x): | 24.76 |
LT Debt/Equity (x): | 0.64 |
Total Debt/Equity (x): | 0.98 |